cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13018/bmr2785
title: Dynamics of Methyl Groups in Proteins As Studied by Proton-Detected 13C NMR Spectroscopy. Application to the Leucine Residues of Staphylococcal Nuclease
DOI: 10.13018/bmr2786
title: Complete Assignment of Aromatic 1H Nuclear Magnetic Resonances of the Tyrosine Residues of Hen Lysozyme
DOI: 10.13018/bmr2787
title: Sequential Individual Resonance Assignments in the 1H Nuclear-Magnetic-Resonance Spectrum of Cardiotoxin VII 2 from Naja mossambica mossambica
DOI: 10.13018/bmr2798
title: Proton NMR Studies of Cucurbita maxima Trypsin Inhibitors: Evidence for pH-Dependent Conformational Change and His25-Tyr27 Interaction
DOI: 10.13018/bmr2799
title: Proton NMR Studies of Cucurbita maxima Trypsin Inhibitors: Evidence for pH-Dependent Conformational Change and His25-Tyr27 Interaction
DOI: 10.6084/m9.figshare.31420433
title: Supplementary Material for: U-Shaped association between the monocyte-to-albumin ratio and overactive bladder

description: Background: This study was designed to examine the relationship between the monocyte-to-albumin ratio (MAR) and overactive bladder (OAB) prevalence.
Methods: This investigation utilized data from the National Health and Nutrition Examination Survey (NHANES), comprising 34,772 participants aged 20 years or older. We employed multivariate logistic regression, smooth curve fitting, subgroup, and sensitivity analyses to examine the relationships between MAR and OAB.
Results: A positive relationship was observed between ln(MAR) and OAB (Overall OR: 1.20; 95% CI: 1.11–1.30). However, a significant U-shaped association was identified through the smooth curve fitting analysis (P for likelihood ratio test &lt;0.001; inflection point at ln(MAR) = -2.64). A threshold effect analysis confirmed this pattern: ln(MAR) was negatively associated with OAB below this threshold (OR: 0.54; 95% CI: 0.34 - 0.87) but positively associated above it (OR: 1.27; 95% CI: 1.16 -1.39). The area under curve (AUC) of ln (MAR) was higher than those for NAR, SIRI, MLR, NMLR, NLR and SII. Compared to various traditional inflammatory markers (such as NLR, MLR, SII, SIRI, etc.), ln (MAR) demonstrated superior discriminative ability for OAB prevalence (AUC = 0.555). Assessment across subgroups showed that the connection between ln(MAR) and OAB was particularly significant in older adults (≥60 years) and individuals with a poverty-income ratio (PIR) of &lt;1.3. 
Conclusions: Our analysis identified a U-Shaped relationship between the MAR and OAB, and the MAR may serve as biomarkers for assessing OAB prevalence.
DOI: 10.6084/m9.figshare.31420433.v1
title: Supplementary Material for: U-Shaped association between the monocyte-to-albumin ratio and overactive bladder

description: Background: This study was designed to examine the relationship between the monocyte-to-albumin ratio (MAR) and overactive bladder (OAB) prevalence.
Methods: This investigation utilized data from the National Health and Nutrition Examination Survey (NHANES), comprising 34,772 participants aged 20 years or older. We employed multivariate logistic regression, smooth curve fitting, subgroup, and sensitivity analyses to examine the relationships between MAR and OAB.
Results: A positive relationship was observed between ln(MAR) and OAB (Overall OR: 1.20; 95% CI: 1.11–1.30). However, a significant U-shaped association was identified through the smooth curve fitting analysis (P for likelihood ratio test &lt;0.001; inflection point at ln(MAR) = -2.64). A threshold effect analysis confirmed this pattern: ln(MAR) was negatively associated with OAB below this threshold (OR: 0.54; 95% CI: 0.34 - 0.87) but positively associated above it (OR: 1.27; 95% CI: 1.16 -1.39). The area under curve (AUC) of ln (MAR) was higher than those for NAR, SIRI, MLR, NMLR, NLR and SII. Compared to various traditional inflammatory markers (such as NLR, MLR, SII, SIRI, etc.), ln (MAR) demonstrated superior discriminative ability for OAB prevalence (AUC = 0.555). Assessment across subgroups showed that the connection between ln(MAR) and OAB was particularly significant in older adults (≥60 years) and individuals with a poverty-income ratio (PIR) of &lt;1.3. 
Conclusions: Our analysis identified a U-Shaped relationship between the MAR and OAB, and the MAR may serve as biomarkers for assessing OAB prevalence.
DOI: 10.13018/bmr2802
title: Determination of the Molecular Dynamics of Alamethicin Using 13C NMR: Implications for the mechanism of Gating of a Voltage-Dependent Channel
DOI: 10.13018/bmr2804
title: Solution Structure of Endothelin-3 Determined Using NMR Spectroscopy
DOI: 10.15468/dl.kqdhrk
title: Occurrence Download

description: A dataset containing 328 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Uzbekistan",
 "TaxonKey is Sapindaceae"
 ]
}

 The dataset includes 328 records from 24 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002736-260225131425191/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31420436
title: Supplementary Material for: Once-weekly Lonapegsomatropin was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial

description: Introduction: Lonapegsomatropin, a prodrug of somatropin, is approved for once-weekly treatment of paediatric growth hormone deficiency (GHD) in the USA and Europe. Here, we report the first trial to assess the efficacy and safety of weekly lonapegsomatropin compared to daily somatropin in treatment-naive Chinese children with GHD. Methods: The briGHt trial was a randomized, open-label, active-controlled, 52-week, phase 3 trial (NCT04326374; CTR20200399) conducted at 17 sites across China. Treatment-naive, prepubertal children with GHD were enrolled and randomized 2:1 to either lonapegsomatropin 0.24 mg hGH/kg/week or equivalent weekly dose of daily somatropin 0.034 mg/kg/day. The primary endpoint was annualized height velocity (AHV) at week 52. Secondary endpoints included change in height standard deviation score (∆HT SDS) from baseline, insulin-like growth factor 1, and safety. Results: 153 participants received treatment. Least-squares (LS) mean ± standard error (±SE) of AHV at week 52 was 10.66 ± 0.22 cm/year for weekly lonapegsomatropin and 9.75 ± 0.26 cm/year for daily somatropin; weekly lonapegsomatropin demonstrated non-inferiority and superiority over daily somatropin, with a difference of 0.91 ± 0.28 cm/year (95% confidence interval: 0.37–1.45; p = 0.0010). LS mean (±SE) of ∆HT SDS was 1.01 ± 0.04 for weekly lonapegsomatropin and 0.83 ± 0.05 for daily somatropin at week 52, favouring lonapegsomatropin from week 13 (p &lt; 0.05) onward. The safety profile was similar between treatment groups. Conclusions: Weekly lonapegsomatropin demonstrated non-inferiority and superiority in efficacy compared to daily somatropin among treatment-naive Chinese children with GHD. The treatment groups showed comparable safety and tolerability profiles.
DOI: 10.6084/m9.figshare.31420436.v1
title: Supplementary Material for: Once-weekly Lonapegsomatropin was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial

description: Introduction: Lonapegsomatropin, a prodrug of somatropin, is approved for once-weekly treatment of paediatric growth hormone deficiency (GHD) in the USA and Europe. Here, we report the first trial to assess the efficacy and safety of weekly lonapegsomatropin compared to daily somatropin in treatment-naive Chinese children with GHD. Methods: The briGHt trial was a randomized, open-label, active-controlled, 52-week, phase 3 trial (NCT04326374; CTR20200399) conducted at 17 sites across China. Treatment-naive, prepubertal children with GHD were enrolled and randomized 2:1 to either lonapegsomatropin 0.24 mg hGH/kg/week or equivalent weekly dose of daily somatropin 0.034 mg/kg/day. The primary endpoint was annualized height velocity (AHV) at week 52. Secondary endpoints included change in height standard deviation score (∆HT SDS) from baseline, insulin-like growth factor 1, and safety. Results: 153 participants received treatment. Least-squares (LS) mean ± standard error (±SE) of AHV at week 52 was 10.66 ± 0.22 cm/year for weekly lonapegsomatropin and 9.75 ± 0.26 cm/year for daily somatropin; weekly lonapegsomatropin demonstrated non-inferiority and superiority over daily somatropin, with a difference of 0.91 ± 0.28 cm/year (95% confidence interval: 0.37–1.45; p = 0.0010). LS mean (±SE) of ∆HT SDS was 1.01 ± 0.04 for weekly lonapegsomatropin and 0.83 ± 0.05 for daily somatropin at week 52, favouring lonapegsomatropin from week 13 (p &lt; 0.05) onward. The safety profile was similar between treatment groups. Conclusions: Weekly lonapegsomatropin demonstrated non-inferiority and superiority in efficacy compared to daily somatropin among treatment-naive Chinese children with GHD. The treatment groups showed comparable safety and tolerability profiles.
DOI: 10.13018/bmr2852
title: 1H-n.m.r. studies of the fibronectin 13kDa collagen-binding fragment Evidence for autonomous conserved typeI and type II domain folds
DOI: 10.6084/m9.figshare.31420439
title: Supplementary Material for: Global pain management trends and barriers to care in hidradenitis suppurativa

description: Introduction: Pain is the most impactful symptom of hidradenitis suppurativa (HS), and understanding its management practices can guide improvements in care. This study aims to describe HS pain severity and associated factors, evaluate pain management practices, and identify barriers to pain management.

Methods: A cross-sectional survey of self-identified adults with HS was conducted from 6/13/2021 to 6/30/2021. Participants were 18 years or older with a confirmed HS diagnosis by a medical provider or a validated questionnaire. Exposures: demographic, clinical factors. Primary outcomes: quality of life (QoL), assessed using the Skindex Mini (0-18 scale), and pain severity, measured via numerical rating scale (NRS, 0-10). Secondary outcomes: pain treatments used and barriers to care.

Results: 890 eligible respondents resided in 5 countries. 96.9% self-identified as female, 74.0% White, 8.3% Black, 2.6% Asian, 5.3% Hispanic, 1.3% American Indian and Native Alaskan, and 7.1% mixed race. Moderate (NRS 4-6) and severe pain (NRS≥7) were significantly associated with reduced QoL, with Skindex Mini scores that were higher for moderate (14.6; 95% CI: 14.0, 15.2) and severe pain (16.1; 95% CI: 15.4, 16.7) compared to mild pain on average (NRS≤3, 10.8; 95% CI: 10.3, 11.3). Younger age, Asian race, difficulty accessing care, and severe disease were independently associated with higher pain (p≤0.002 for all). Reported barriers to pain management included providers not asking about pain, poor provider knowledge, and perceived unwillingness to treat pain. 38.4% of participants reported they had never received a prescription for pain medication. Pain prescriptions were most commonly received from primary care physicians (22.5%) or dermatologists (13.3%), with severe pain linked to increased use of opioids, tramadol, and antiepileptics to treat HS pain (p&lt;0.05 for all).

Conclusion: Pain in HS is linked to lower QoL and barriers to management, emphasizing the need for evidence-based, patient-centered approaches to enhance pain care and address treatment gaps.
DOI: 10.6084/m9.figshare.31420439.v1
title: Supplementary Material for: Global pain management trends and barriers to care in hidradenitis suppurativa

description: Introduction: Pain is the most impactful symptom of hidradenitis suppurativa (HS), and understanding its management practices can guide improvements in care. This study aims to describe HS pain severity and associated factors, evaluate pain management practices, and identify barriers to pain management.

Methods: A cross-sectional survey of self-identified adults with HS was conducted from 6/13/2021 to 6/30/2021. Participants were 18 years or older with a confirmed HS diagnosis by a medical provider or a validated questionnaire. Exposures: demographic, clinical factors. Primary outcomes: quality of life (QoL), assessed using the Skindex Mini (0-18 scale), and pain severity, measured via numerical rating scale (NRS, 0-10). Secondary outcomes: pain treatments used and barriers to care.

Results: 890 eligible respondents resided in 5 countries. 96.9% self-identified as female, 74.0% White, 8.3% Black, 2.6% Asian, 5.3% Hispanic, 1.3% American Indian and Native Alaskan, and 7.1% mixed race. Moderate (NRS 4-6) and severe pain (NRS≥7) were significantly associated with reduced QoL, with Skindex Mini scores that were higher for moderate (14.6; 95% CI: 14.0, 15.2) and severe pain (16.1; 95% CI: 15.4, 16.7) compared to mild pain on average (NRS≤3, 10.8; 95% CI: 10.3, 11.3). Younger age, Asian race, difficulty accessing care, and severe disease were independently associated with higher pain (p≤0.002 for all). Reported barriers to pain management included providers not asking about pain, poor provider knowledge, and perceived unwillingness to treat pain. 38.4% of participants reported they had never received a prescription for pain medication. Pain prescriptions were most commonly received from primary care physicians (22.5%) or dermatologists (13.3%), with severe pain linked to increased use of opioids, tramadol, and antiepileptics to treat HS pain (p&lt;0.05 for all).

Conclusion: Pain in HS is linked to lower QoL and barriers to management, emphasizing the need for evidence-based, patient-centered approaches to enhance pain care and address treatment gaps.
DOI: 10.13018/bmr2853
title: 1H-n.m.r. studies of the fibronectin 13kDa collagen-binding fragment Evidence for autonomous conserved typeI and type II domain folds
DOI: 10.13018/bmr2856
title: Sequential 1H NMR Assignments of Kistrin, a Potent Platelet Aggregation Inhibitor and Glycoprotein IIB-IIIa Antagonist
DOI: 10.15468/dl.8rj6ah
title: Occurrence Download

description: A dataset containing 13 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "DistanceFromCentroidInMeters is greater than or equal to 2000",
 "Geometry POLYGON ((105.610544 14.999999, 179.999961 14.999999, 179.999961 65.08290100000001, 105.610544 65.08290100000001, 105.610544 14.999999))",
 "TaxonKey is Dascyllus melanurus"
 ]
}

 The dataset includes 13 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002737-260225131425191/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31420445
title: Supplementary Material for: Severe Periocular Inflammatory Reaction Mimicking Necrotizing Fasciitis Following Hyaluronic Acid Microinjections: A Case Report and Literature Review

description: Introduction
Hyaluronic acid (HA) fillers are widely utilized in aesthetic medicine for facial rejuvenation, including in the periocular region. Although generally considered safe, severe inflammatory responses can occur. This report describes a case of a 42-year-old woman who developed a significant periocular reaction following HA microinjections, clinically resembling necrotizing fasciitis.
Case Presentation
The patient, with no significant medical or ophthalmic history, presented to the emergency department with acute periocular swelling, redness, and inability to open her right eye three hours after HA microinjections. Clinical examination revealed marked periorbital edema, chemosis, and restricted ocular motility in the right eye. The severity of the presentation initially suggested necrotizing fasciitis. A CT scan indicated preseptal cellulitis without post-septal involvement. Treatment with intravenous antibiotics, systemic corticosteroids, antihistamines, and topical therapies led to significant improvement.
Conclusion
This case highlights the need to recognize severe inflammatory reactions following periocular HA injections, which may mimic life-threatening conditions. Timely intervention and systematic evaluation are essential for achieving favorable outcomes.
DOI: 10.6084/m9.figshare.31420445.v1
title: Supplementary Material for: Severe Periocular Inflammatory Reaction Mimicking Necrotizing Fasciitis Following Hyaluronic Acid Microinjections: A Case Report and Literature Review

description: Introduction
Hyaluronic acid (HA) fillers are widely utilized in aesthetic medicine for facial rejuvenation, including in the periocular region. Although generally considered safe, severe inflammatory responses can occur. This report describes a case of a 42-year-old woman who developed a significant periocular reaction following HA microinjections, clinically resembling necrotizing fasciitis.
Case Presentation
The patient, with no significant medical or ophthalmic history, presented to the emergency department with acute periocular swelling, redness, and inability to open her right eye three hours after HA microinjections. Clinical examination revealed marked periorbital edema, chemosis, and restricted ocular motility in the right eye. The severity of the presentation initially suggested necrotizing fasciitis. A CT scan indicated preseptal cellulitis without post-septal involvement. Treatment with intravenous antibiotics, systemic corticosteroids, antihistamines, and topical therapies led to significant improvement.
Conclusion
This case highlights the need to recognize severe inflammatory reactions following periocular HA injections, which may mimic life-threatening conditions. Timely intervention and systematic evaluation are essential for achieving favorable outcomes.
DOI: 10.13018/bmr2858
title: Comparisons of Ring-Current Shifts Calculated from the Crystal Structure of Egg White Lysozyme of Hen with the Proton Nuclear Magnetic Resonance Spectrum of Lysozyme in Solution
DOI: 10.13018/bmr2868
title: Sequential assignment of the proton NMR spectrum of isolated alpha(CO) chains from human adult hemoglobin
DOI: 10.13018/bmr2917
title: Study of Tryptophan Residues of Lysozyme Using 1H Nuclear Magnetic Resonance
DOI: 10.13018/bmr2928
title: 3D structure of bovine pancreatic ribonuclease A in aqueous solution: An approach to tertiary structure determination from a small basis of 1H NMR NOE correlations
DOI: 10.13018/bmr2935
title: 1H NMR Study of the Molecular and Electronic Structure of Paramagnetic Iron Chlorin Complexes of Myoglobin: Dynamic Heterogeneity of the Heme Pocket
DOI: 10.13018/bmr2936
title: 1H NMR Study of the Molecular and Electronic Structure of Paramagnetic Iron Chlorin Complexes of Myoglobin: Dynamic Heterogeneity of the Heme Pocket
DOI: 10.13018/bmr2939
title: Solution Structures of Cyclic and Dicyclic Analogues of Growth Hormone Releasing factor as Determined by Two-Dimensional NMR an CD Spectroscopies and Constrained Molecular Dynamics
DOI: 10.13018/bmr2940
title: Solution Structures of Cyclic and Dicyclic Analogues of Growth Hormone Releasing factor as Determined by Two-Dimensional NMR an CD Spectroscopies and Constrained Molecular Dynamics
DOI: 10.6084/m9.figshare.31420448
title: Supplementary Material for: House Dust Mite Sublingual Immunotherapy for Allergic Rhinoconjunctivitis: Comprehensive Review and Meta-Analytical Evidence

description: Background: House dust mites (HDM) are a primary trigger of allergic rhinoconjunctivitis (ARC), a common condition associated with substantial symptom burden and impaired quality of life. Although sublingual immunotherapy (SLIT) of HDM extracts has shown therapeutic potential, its overall efficacy and safety profile in adults and adolescents with ARC remains incompletely defined. We aimed to assess the efficacy and safety of HDM SLIT in adults and adolescents with ARC.
Methods: We conducted a systematic search of PubMed, Scopus, Web of Science (WOS), and Cochrane CENTRAL databases up to May 2025. We included studies comparing HDM SLIT to placebo or pharmacotherapy. The main efficacy outcomes were the combined symptom and medication score (CSMS), rhinitis symptom score (RSS), rhinitis medication score (RMS), and rhinoconjunctivitis quality of life questionnaire (RQLQ). Safety was assessed by analyzing treatment-related adverse events (AEs), serious, severe, and local AEs. A random-effects model was used to pool standardized mean differences (SMD) and risk ratios (RR).
Results: A total of 45 studies involving 30,288 participants were included in the systematic review, with 28 providing data for the meta-analysis. SLIT significantly improved multiple efficacy outcomes, including RSS and RMS, with a pooled SMD and 95% CI (-0.98, [-1.65, -0.31], p &lt; 0.001) and (-1.00, [-1.80, -0.20], p = 0.01), respectively. SLIT was associated with a higher risk of treatment-related AEs with a pooled RR and 95% CI (1.16, [1.02, 1.33], p = 0.02), which were predominantly mild, local, and transient.
Conclusion: This study confirms that standardized HDM SLIT is an effective and safe disease-modifying therapy for adults and adolescents with ARC. It provides clinically meaningful reductions of symptoms and medication use and improves quality of life. The favorable safety profile supports its use as a foundational treatment in the management of HDM-induced ARC.
DOI: 10.6084/m9.figshare.31420448.v1
title: Supplementary Material for: House Dust Mite Sublingual Immunotherapy for Allergic Rhinoconjunctivitis: Comprehensive Review and Meta-Analytical Evidence

description: Background: House dust mites (HDM) are a primary trigger of allergic rhinoconjunctivitis (ARC), a common condition associated with substantial symptom burden and impaired quality of life. Although sublingual immunotherapy (SLIT) of HDM extracts has shown therapeutic potential, its overall efficacy and safety profile in adults and adolescents with ARC remains incompletely defined. We aimed to assess the efficacy and safety of HDM SLIT in adults and adolescents with ARC.
Methods: We conducted a systematic search of PubMed, Scopus, Web of Science (WOS), and Cochrane CENTRAL databases up to May 2025. We included studies comparing HDM SLIT to placebo or pharmacotherapy. The main efficacy outcomes were the combined symptom and medication score (CSMS), rhinitis symptom score (RSS), rhinitis medication score (RMS), and rhinoconjunctivitis quality of life questionnaire (RQLQ). Safety was assessed by analyzing treatment-related adverse events (AEs), serious, severe, and local AEs. A random-effects model was used to pool standardized mean differences (SMD) and risk ratios (RR).
Results: A total of 45 studies involving 30,288 participants were included in the systematic review, with 28 providing data for the meta-analysis. SLIT significantly improved multiple efficacy outcomes, including RSS and RMS, with a pooled SMD and 95% CI (-0.98, [-1.65, -0.31], p &lt; 0.001) and (-1.00, [-1.80, -0.20], p = 0.01), respectively. SLIT was associated with a higher risk of treatment-related AEs with a pooled RR and 95% CI (1.16, [1.02, 1.33], p = 0.02), which were predominantly mild, local, and transient.
Conclusion: This study confirms that standardized HDM SLIT is an effective and safe disease-modifying therapy for adults and adolescents with ARC. It provides clinically meaningful reductions of symptoms and medication use and improves quality of life. The favorable safety profile supports its use as a foundational treatment in the management of HDM-induced ARC.
DOI: 10.13018/bmr2941
title: Solution Structures of Cyclic and Dicyclic Analogues of Growth Hormone Releasing factor as Determined by Two-Dimensional NMR an CD Spectroscopies and Constrained Molecular Dynamics
DOI: 10.13018/bmr2948
title: Evidence for the presence of a secondary structure at the dibasic processing site of prohormone: the pro-ocytocin model
DOI: 10.13018/bmr2950
title: Assessment of cheY binding regions using 2D NMR and paramagnetic ligands